industry pr

Press release news from the public relations clients of Tiziani Whitmyre, Inc.

Posts Tagged ‘DNA sequencing’


Thursday, January 15th, 2009

“Biology in Pico-Liter Droplets” is Focus of Presentation at LabAutomation 2009

LEXINGTON, MASS. – Jan. 14, 2009 – Darren R. Link, Ph.D., of RainDance Technologies, Inc., will present “Biology in Pico-Liter Droplets,” a discussion of the commercialization of the use of picoliter droplets in microfluidic channels for applications in the life sciences, at the LabAutomation2009 conference on Wednesday, January 28, 2009, in Palm Springs, Calif.

RainDance Technologies is a provider of innovative microdroplet-based solutions which enable and benefit biological applications utilized in human health and disease research.

“In typical applications, cells, nucleic acids, enzymes, or other reagents are encapsulated in aqueous phase droplets dispersed in a fluorinated carrier oil. These droplets range from sub-picoliter to tens of nanoliters in volume, and are manipulated on an individual basis to perform bioassays. Manipulations such as adding reagents or sorting droplets based on their optical properties are achieved solely through the application of external electric fields. Since electric fields can be turned on or off at very high speeds, sorting rates exceeding several thousand per second are readily achieved. We will introduce the techniques used to generate and manipulate droplets and show several of the biological applications that are enabled by this technology,” said Dr. Link.

Dr. Link is Co-Founder and Vice President, Research and Development, RainDance Technologies (http://www.raindancetech.com/). He holds a B.S. degree in physics from Montana State University and a Ph.D. in physics from the University of Colorado. Before joining RainDance, he spent two years at Harvard University as a postdoctoral scientist studying soft materials physics in the department of physics and division of engineering and applied sciences. Dr. Link spent two years at Tokyo Institute of Technology as a postdoctoral scientist studying liquid crystalline materials. He has received grant funding from the U.S. Defense Advanced Research Projects Agency and participated in the National Science Foundation’s U.S.-Japan exchange program for young scientists in Nanotechnology. Dr. Link has co-authored more than 45 peer-reviewed articles and 10 patent applications. He also serves on the Industrial Advisory Board of the Vanderbilt Institute for Integrative Biosystems Research and Education.

Dr. Link will present “Biology in Pico-Liter Droplets” as part of the Micro- and Nanotechnologies conference track LabAutomation2009, Wednesday, January 28, 2009, from 9:30 AM to 10:00 AM in the Pasadena room of the Wyndham Hotel in Palm Springs, Calif.

LabAutomation2009 (www.labautomation.org/LA09), the world’s leading conference and exhibition on emerging laboratory technologies, runs January 24-28, 2009.

About RainDance Technologies
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s RainStorm tm technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information about RainDance Technologies, please visit http://www.raindancetech.com/.

# # #

RainStorm(TM) is a trademark of RainDance Technologies, Inc.

Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations/

bookmark to del.icio.us

Technorati tags: , , , , , , , , ,

Tags: , , , , , , , ,
Posted in Biosciences |


Wednesday, December 10th, 2008

RainDance Technologies Delivers RDT 1000, Sequence Enrichment Solution to Broad Institute

LEXINGTON, MASSACHUSETTS, U.S.A., December 10, 2008 — RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced that the Eli and Edythe L. Broad Institute in Cambridge, Massachusetts, will become an early access partner for its new RDT 1000 and Sequence Enrichment Solution.

Under the Early Access Partner program, RainDance will deliver to the Broad Institute its RDT 1000, consumables kits, and expert training for sequence enrichment. This will include custom PCR primer libraries designed to selectively amplify loci of interest for the Institute’s breakthrough genomic research initiatives. In addition, the Institute will investigate the application of the RDT 1000 for experiments related to the human microbiome.

“The program provides an opportunity for some of the world’s leading scientists in genomic research to become experienced with our technology months prior to its commercial launch,” said Chris McNary, President and Chief Executive Officer of RainDance Technologies. “Their work also represents further recognition of our platform’s unique capabilities to extend into other targeted sequencing applications of significant biological importance.”

The RDT 1000 and Sequence Enrichment Solution utilize RainDance’s breakthrough RainStormTM microdroplet-based technology platform. The simplicity and speed of the technology are designed to maximize the efficiency of next-generation DNA sequencing workflows. The RDT 1000 generates picoliter volume PCR reactions at the rate of 10 million discrete reactions per hour. The high-speed sample processing is further enhanced by the fact that the Sequence Enrichment Solution utilizes a library of PCR primers in droplets enabling the amplification of hundreds to thousands of genomic loci in a single tube. The RainStorm format avoids the limitations of traditional multiplex hybridization and amplification technologies. RainDance’s solution minimizes process-induced bias or error and requires only a few micrograms of genomic DNA.

“We are anticipating our solution will significantly enhance the Broad Institute’s genomics research program,” said McNary. “It is our expectation their experience will further reinforce the benefits of our solution in biomedical research.”

About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit http://www.raindancetech.com/.

# # #

Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations/

bookmark to del.icio.us

Technorati tags: , , , ,

Tags: , , , ,
Posted in Biosciences |


Wednesday, November 12th, 2008

RainDance Technologies Introduces Sequence Enrichment Solution

PHILADELPHIA, PENNSYLVANIA, USA, November 12, 2008 — RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today officially introduced its Sequence Enrichment Solution for targeted sequencing applications of the human genome.

RainDance unveiled the solution at the 58th Annual Meeting of the American Society of Human Genetics (ASHG) in Philadelphia, Penn.

“The RainDance Sequence Enrichment Solution represents a true paradigm shift forward in the sequencing of targeted regions of the human genome,” said Chris McNary, President and Chief Executive Officer of RainDance Technologies.

“Our solution will enable the high-resolution analysis of genetic variation between individuals within populations at a level unmatched by current methodologies. It dramatically improves sample uniformity and reduces the selection bias typically associated with targeted sequencing,” McNary said.

Targeted sequencing is one of the fastest growing applications for next-generation sequencing technology. Sequence enrichment is a critical step in an efficient targeted sequencing workflow. The RainDance Sequence Enrichment Solution allows researchers to isolate specific regions of the genome for subsequent sequencing.

The RainDance Sequence Enrichment Solution consists of the following:

The RDT 1000, also introduced today at ASHG, generates picoliter volume discrete PCR reactions in droplets at the unprecedented rate of 10 million per hour. It amplifies hundreds to thousands of genomic loci with high specificity and uniformity.

Customer-Specified DNA Primer Libraries enable the amplification of hundreds to thousands of genomic loci in a single tube. RainDance clients will design and order these libraries specifically for their research applications.

Reagents, consumables, and services provide a complete workflow solution implemented in the laboratory.

“The Sequence Enrichment Solution minimizes errors and maximizes the efficiency of PCR by leveraging the sensitivity and specificity of this proven methodology while avoiding the limitations of alternative multiplex hybridization and amplification techniques,” said McNary.

“It significantly reduces study time and costs while requiring only a few micrograms of sample DNA. Researchers can utilize our solution to either significantly shorten study time, or to enhance study quality by generating additional samples in the same time within the same research budget,” he said.

The solution fits seamlessly into any workflow and dramatically improves process output and data quality. Its “open” design easily integrates with all next-generation DNA sequencing platforms.

The company plans to commercially launch the solution during the first quarter of 2009.

Under RainDance’s Early Access Partner program, the RainDance Sequence Enrichment Solution has been delivered and is in use at selected premier organizations engaged in genomic research, including The Genome Sequencing Center (GSC) at the Washington University School of Medicine in St. Louis, Missouri, and the J. Craig Venter Institute (JCVI) in Rockville, Maryland.

For more information about RainDance Technologies and its revolutionary new Sequence Enrichment Solution and RDT 1000, visit booth 825 at ASHG 2008, or the company’s website at www.raindancetech.com.

About RainDance Technologies, Inc.
RainDance Technologies, Inc. is a provider of innovative microdroplet-based biological solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. For more information, visit www.raindancetech.com.

# # #

Download high resolution images from: www.flickr.com/photos/10956940@N08/sets/72157608504468068/

Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations/

bookmark to del.icio.us

Technorati tags: , , , , ,

Tags: , , , , ,
Posted in Biosciences |


Wednesday, November 12th, 2008

RainDance Technologies Introduces the RDT 1000

PHILADELPHIA, PENNSYLVANIA, USA, November 12, 2008 — RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today officially introduced its new RDT 1000, the centerpiece of its Sequence Enrichment Solution for the targeted genomic sequencing market.

RainDance unveiled the RDT 1000 at the 58th Annual Meeting of the American Society of Human Genetics (ASHG) in Philadelphia, Penn.

“We believe the RDT 1000 represents a breakthrough in accelerating the sequencing of targeted regions of the human genome,” said Chris McNary, President and Chief Executive Officer of RainDance Technologies. “It delivers exceptionally high sequencing efficiency, enabling reduced workflow costs and faster time to results.”

Targeted sequencing is one of the fastest growing applications for next-generation sequencing technology. Sequence enrichment is a critical step in an efficient targeted sequencing workflow. The RainDance Sequence Enrichment Solution allows researchers to isolate specific regions of the genome for subsequent sequencing.

The RDT 1000, with RainStorm(TM) microdroplet-based technology, amplifies hundreds to thousands of genomic loci with high specificity and uniformity. It leverages the sensitivity and specificity of polymerase chain reaction (PCR) methodology, a tested and trusted process in laboratories worldwide, while avoiding the limitations of alternative multiplex hybridization and amplification techniques. The RDT 1000 generates replicate reactions to minimize error and ensure confidence in sequencing results.

“Researchers can utilize the RDT 1000 to either greatly reduce study time, or to improve study quality by running more samples in the same time within the same research budget,” said McNary.

The RDT 1000 fits seamlessly into any targeted sequencing workflow and dramatically improves process output and data quality. It maximizes the efficiency of the workflow by minimizing the requirement to perform additional sequencing to ensure adequate coverage for the loci of interest.

“The RDT 1000’s ‘open’ design easily integrates with all next-generation DNA sequencing platforms,” McNary said.

Under RainDance’s Early Access Partner program, the RDT 1000 has been delivered and is in use at selected premier organizations engaged in genomic research, including The Genome Sequencing Center (GSC) at the Washington University School of Medicine in St. Louis, Missouri, and the J. Craig Venter Institute (JCVI) in Rockville, Maryland.

RainDance plans to commercially launch the RDT 1000 in the first quarter of 2009.

To learn more about RainDance Technologies and its revolutionary new RDT 1000 and Sequence Enrichment Solution, visit booth 825 at ASHG 2008, or the company’s website at http://www.raindancetech.com/.

About RainDance Technologies, Inc.
RainDance Technologies, Inc. is a provider of innovative microdroplet-based biological solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. For more information, visit http://www.raindancetech.com/.

# # #

Download high resolution images from: www.flickr.com/photos/10956940@N08/sets/72157608504468068/

Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations/

bookmark to del.icio.us

Technorati tags: , , , , ,

Tags: , , , , ,
Posted in Biosciences |


Thursday, November 6th, 2008

RainDance Technologies Delivers RDT 1000, Sequence Enrichment Solution to The Genome Center at Washington University School of Medicine in St. Louis

LEXINGTON, MASSACHUSETTS, U.S.A., November 6, 2008 — RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced that it has shipped its new RDT 1000 instrument and Sequence Enrichment application to The Genome Center (GC) at the Washington University School of Medicine in St. Louis, a world leader in genomics research.

Under RainDance’s Early Access Partner program, RainDance will provide its new RDT 1000 and expert training to the GC, along with customized PCR primer libraries to selectively amplify loci of interest for their research initiatives.

Elaine Mardis, Ph.D., Co-Director of The Genome Center, said GC researchers “will be applying the platform in our large-scale targeted sequencing studies and are enthusiastic about reporting their experiences and results.”

“If the technology delivers as promised, RainDance Technology stands to significantly advance the art of targeted sequencing,” Dr. Mardis said.

“As a leader in advancing genome sequencing and its application to human health, we’re very excited about the participation of the GC in our Early Partnership Program. Their input and experience will be invaluable as we introduce the RainStorm platform to the world’s DNA sequencing market,” said Chris McNary, President and Chief Executive Officer of RainDance Technologies.

RainDance plans to commercially launch the RainDance platform in the first quarter of 2009, McNary added.

The RDT 1000 and Sequence Enrichment application utilize RainDance’s breakthrough RainStorm droplet-based technology platform. The simplicity, speed, and minute volume of the technology are designed to maximize the efficiency of next-generation DNA sequencing workflows. The RDT 1000 generates picoliter volume PCR reactions at the rate of 10 million discrete reactions per hour. The high-speed sample processing is further enhanced by the fact that the Sequence Enrichment application utilizes a library of PCR primers in droplets enabling the amplification of hundreds to thousands of genomic loci in a single tube. The RainStorm format avoids the limitations of traditional multiplex hybridization and amplification technologies. RainDance’s solution minimizes process-induced bias or error and requires only a few micrograms of genomic DNA.

About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit http://www.raindancetech.com/.

# # #

Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations/

bookmark to del.icio.us

Technorati tags: , , , , ,

Tags: , , , , ,
Posted in Biosciences |


Monday, November 3rd, 2008

RainDance Technologies to Present Workshop on Sequence Enrichment Using Innovative Microdroplet-Based Solutions at ASHG 2008

LEXINGTON, MASS. – November 3, 2008 – RainDance Technologies will present a workshop on sequence enrichment using innovative microdroplet-based solutions at the American Society of Human Genetics (ASHG) 58th Annual Meeting in Philadelphia on Thursday, November 13th.

Recent advances in DNA sequencing technologies have improved accuracy and dramatically reduced cost. However, even with the improved efficiency of “second generation” systems, sequencing thousands of human genomes across various phenotypes is still economically unrealistic. To exploit the full potential of new sequencing techniques, a robust method for isolating biologically relevant genomic loci on the megabase scale will be required.

Analogous to what the massively parallel sequencing technologies have done to improve the efficiency of DNA sequencing, RainDance Technologies has developed a platform to enable the use of PCR for high-throughput amplification of targeted genomic sequences.

The workshop at ASHG 2008 will explain the application of this new technology.

“The Sequence Enrichment application leverages our RainStorm™ technology to manipulate picoliter volume droplets in disposable chips. We will present the use of this novel method for enrichment of genomic loci with minimal selection bias prior to sequencing, demonstrating the utility of this approach for the routine application of targeted sequencing,” said Jeff Olson, Manager of Nucleic Acid Applications, RainDance Technologies. Olson will lead the workshop.

To register for the workshop, “Sequence Enrichment Using Droplet-Based Microfluidics,” visit: www.raindancetechnologies.com/ashgworkshop. The workshop will be held at the American Society of Human Genetics (ASHG) 58th Annual Meeting, Thursday, November 13, 2008, from 1:00 -2:00 p.m. at the Philadelphia Marriott, 4th floor, Room 411.

To learn more about RainDance Technologies and its revolutionary new RainStorm™ innovative microdroplet-based technology, visit booth 825 at ASHG 2008, or the company’s website at http://www.raindancetech.com/.

About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit http://www.raindancetech.com/.

# # #

Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations/

bookmark to del.icio.us

Technorati tags: , , , , ,

Tags: , , , , , , , ,
Posted in Biosciences |


Monday, November 3rd, 2008

RainDance Technologies Delivers RDT 1000, Sequence Enrichment Solution to JCVI

LEXINGTON, MASSACHUSETTS, U.S.A., October 30, 2008 — RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced that the J. Craig Venter Institute (JCVI), a not for profit genomic research organization located in Rockville, MD and La Jolla, CA, will become an early access partner for its new RDT 1000 instrument and Sequence Enrichment application.

Under the Early Access Partner program, RainDance delivers its RDT 1000 and expert training to selected premier organizations in genomic research. RainDance will also provide customized PCR primer libraries designed to selectively amplify loci of interest for research initiatives at JCVI. “The program provides an opportunity for some of the world’s leading scientists in genomic research to become experienced with our technology prior to our commercial launch,” said Chris McNary, President and Chief Executive Officer of RainDance Technologies.

The RDT 1000 and Sequence Enrichment application utilizes RainDance’s breakthrough RainStorm™ droplet-based technology platform. The simplicity, speed, and minute volume of the technology are designed to maximize the efficiency of JCVI’s next-generation DNA sequencing workflow. The RDT 1000 generates picoliter volume PCR reactions at the rate of 10 million discrete reactions per hour. The high-speed sample processing is further enhanced by the fact that the Sequence Enrchment application utilizes a library of PCR primers in droplets enabling the amplification of hundreds to thousands of genomic loci in a single tube. The RainStorm format avoids limitations of traditional multiplex hybridization and amplification technologies. The RainDance solution minimizes process-induced bias or error and requires only a few micrograms of genomic DNA.

JCVI scientists “will incorporate the RainStorm application into the various large-scale targeted sequencing studies as part of our on-going research programs in human genomic medicine,” said Robert L. Strausberg, Ph.D., Deputy Director and Group Leader, Genomic Medicine, JCVI.

“We are looking forward to working closely with JCVI as they integrate our technology to support their breakthrough research,” McNary said. “We’re also anxiously anticipating the results of the performance of our technology in their hands”. It is our expectation their experience will further reinforce the RainStorm technology platform’s benefits in human health and disease research,” he said.

“This expert experience will be invaluable as we prepare for our commercial launch in the first quarter of 2009,” McNary added.

About the J. Craig Venter Institute
The JCVI is a not-for-profit research institute in Rockville, MD and La Jolla, CA dedicated to the advancement of the science of genomics; the understanding of its implications for society; and communication of those results to the scientific community, the public, and policymakers. Founded by J. Craig Venter, Ph.D., the JCVI is home to approximately 400 scientists and staff with expertise in human and evolutionary biology, genetics, bioinformatics/informatics, information technology, high-throughput DNA sequencing, genomic and environmental policy research, and public education in science and science policy. The legacy organizations of the JCVI are: The Institute for Genomic Research (TIGR), The Center for the Advancement of Genomics (TCAG), the Institute for Biological Energy Alternatives (IBEA), the Joint Technology Center (JTC), and the J. Craig Venter Science Foundation. The JCVI is a 501 (c) (3) organization. For additional information, please visit http://www.jcvi.org/cms/home/.

About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable. The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt proven assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England and the ESPCI in Paris.

For more information, please visit http://www.raindancetech.com/.

# # #

Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations/

bookmark to del.icio.us

Technorati tags: , , , , ,

Tags: , , , , ,
Posted in Biosciences |


Friday, September 26th, 2008

RainDance Dedicates New Headquarters, Manufacturing Facility

LEXINGTON, MASS. – Sept. 26, 2008 — RainDance Technologies, Inc., a provider of innovative droplet-based microfluidic solutions for human health and disease research, today dedicated its new headquarters and operations building and unveiled its new RDT 1000 instrument.

Keynoting the event was Sir Richard Roberts, 2003 Nobel Prize winner for physiology and medicine and Founder and Chief Scientific Officer of New England Biolabs. Chris McNary, President and Chief Executive Officer, RainDance Technologies; Daniel O’Connell, Secretary of Housing and Economic Development, Commonwealth of Massachusetts; and Robert Coughlin, President and Chief Executive Officer, Massachusetts Biotechnology Council, also spoke at the event.

“The development of new technology has driven the pace of discovery in health and human disease research,” said Sir Richard Roberts. “RainDance technology has the potential to accelerate breakthroughs in genomic research and fulfill the promise of personalized medicine.”

RainDance is among the first companies to relocate to Massachusetts under Governor Deval Patrick’s innovative Life Sciences Initiative. The company cited the initiative as a major factor in moving the company’s operations from Connecticut to Massachusetts.

“Today, our dream of bringing innovative products to market is becoming a reality here in Lexington, as we dedicate this new 28-thousand square foot facility,” said Chris McNary, president and chief executive officer, RainDance Technologies. “We liked what we saw in Massachusetts. Its access to life science talent, state research grants, and the customer base of the greater Boston-Cambridge area were important requirements for our growing company,” said McNary.

RainDance cited Secretary O’Connell, the Governor’s Office, and the Massachusetts Biotechnology Council for making the company’s relocation a smooth and seamless transition.

“Strong public-private partnerships have made Massachusetts a leader in life sciences and personalized medicine with a growing base of companies and research institutions,” said O’Connell. “RainDance will play an important role in continuing that leadership.”

“We are proud to have RainDance Technologies join the impressive list of life sciences companies basing their operations in Massachusetts,” said Coughlin. “Their innovative technology and unique knowledge will add vitality to our biotechnology community.”

During the ceremony, the company unveiled a rendering of the RDT 1000 instrument, the centerpiece of its new Sequence Enrichment solution for the targeted genomic sequencing market.

“Soon, we will be delivering our sequence enrichment solution to early access partners representing some of the nation’s leading genome centers,” said McNary. “This technology will be introduced to the market during the fourth quarter, with commercial launch scheduled for the first quarter of 2009.”

RainDance’s new RainStorm™ droplet-based microfluidic technology has broad use in the prediction and prevention of human disease. The simplicity, speed, and capacity of the technology will enable numerous uses in biomedical applications, including genomics research, gene expression analysis, compound screening, and biomarker detection.

About RainDance Technologies, Inc.
RainDance Technologies is a provider of innovative droplet-based microfluidic solutions for human health and disease research. The simplicity and speed of the company’s exciting new technology platform enable researchers to design experiments in ways that were previously unaffordable or unimaginable.

The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board. RainDance advisers include three Nobel Prize winners: Jean-Marie Lehn (Chemistry, 1987), Aaron Klug (Chemistry, 2002), and Sir Richard Roberts (Physiology or Medicine, 1993), as well as Sir Gregory Winter, joint head of the British Division of Protein and Nucleic Acids Chemistry at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge.

For more information, please visit www.raindancetech.com.

# # #

Public Relations contact: Tiziani Whitmyre, Inc., www.tizinc.com/services/public-relations/

bookmark to del.icio.us

Technorati tags: , , , , , , , ,

Tags: , , , , , , , ,
Posted in Biosciences |


Monday, September 22nd, 2008

RainDance Technologies to Dedicate New Biomedical Technology Facility in Lexington

MEDIA ALERT — UPCOMING NEWS EVENT
RainDance Technologies to Dedicate New Biomedical Technology Facility in Lexington

– Biomedical technology innovator relocates to Mass. based upon Gov. Deval Patrick’s Life Sciences Initiative –

  • WHEN: Friday, Sept. 26, 2008, 3:00 p.m. to 5:00 p.m. EDT
  • WHERE: 44 Hartwell Avenue, Lexington, Mass.

RainDance Technologies, Inc., a provider of innovative droplet-based microfluidic solutions for human health and disease research, will dedicate its new headquarters and commercial and manufacturing operations on Friday, Sept. 26th in Lexington, Mass. at 3:00 p.m.

RainDance’s 28,000-square-foot building in Lexington will more than double its former space in Guilford, Conn. RainDance plans to increase its workforce by some 50 percent – adding new biologists and chemists, mechanical engineers and technicians, software programmers, customer service representatives, and administrative support – and will employ nearly 100 within the year.

Company officials made the decision to relocate to Massachusetts based on Governor Deval Patrick’s Life Sciences Initiative.

RainDance will also announce a collaboration with a major pharmaceutical company to develop a new droplet-based methodology for the drug discovery process.

AgendaRemarks:

  • Sir Richard Roberts, Nobel Laureate, Physiology/ Medicine, 1993, RainDance Technologies Scientific Advisory Board
  • Daniel O’Connell, Massachusetts Housing and Economic Development Secretary
  • Christopher McNary, RainDance Technologies President and Chief Executive Officer
  • Robert Coughlin, president of the Massachusetts Biotechnology Council

A tour of our new facilities and reception will follow.

RainDance’s new RainStorm™ droplet-based microfluidic technology has broad use in the prediction and prevention of human disease. The simplicity, speed, and capabilities of the technology will enable researchers to design experiments in ways previously unaffordable or unimaginable. RainStorm technology will find numerous uses in biomedical applications, including genomics research, gene expression analysis, compound screening, and biomarker detection.

RainDance was founded by scientists from Harvard University, the Medical Research Centre in Cambridge, England, and the ESPCI in Paris, and the company’s scientific advisers include three Nobel Prize winners plus a pioneer in protein engineering who has been knighted for services to molecular biology.

For further information: Don Goncalves, dgoncalves@tizinc.com, 781-793-9380; Cortney Lusignan, clusignan@tizinc.com, 781-793-9380.

# # #

Public Relations contact: Tiziani Whitmyre, Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , , , , , , , , , ,

Tags: , , , , , , , ,
Posted in Biosciences |


Wednesday, August 13th, 2008

RainDance Technologies Appoints Olex Vice President, System Development

LEXINGTON, Mass., Aug 13, 2008 — RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the appointment of Michael B. Olex as Vice President, System Development, effective immediately.

“As RainDance introduces its exciting RainStorm(TM) droplet-based technology to market, Mr. Olex will play a key leadership role in designing, developing, and integrating complete systems for commercialization, including instrumentation, consumables, and reagents,” said Chris McNary, President and Chief Executive Officer, RainDance Technologies. “He will immediately focus on our Sequence Enrichment application for targeted genomic sequencing that will be launched later this year. With his deep experience in life sciences management, Mr. Olex will establish productive, efficient product transfer procedures from engineering to manufacturing, including the development of manufacturing processes,” McNary said.

Olex joins RainDance from BioTrove, where he was Vice President, Manufacturing, and established the company’s OpenArray(TM) consumable and instrumentation manufacturing departments. He also served as Senior Vice President at U.S. Genomics; President of International Light; Director, Business Projects at Applied Biosystems; and Vice President of Manufacturing at PerSeptive Biosystems. Olex holds a master of business administration degree from Case Western Reserve University, a master of science degree in electrical engineering from Cleveland State University, and a bachelor’s degree in electrical engineering from the University of Detroit.

About RainDance Technologies, Inc.
RainDance Technologies is a provider of innovative droplet-based solutions for human health and disease research. The speed and simplicity of the company’s exciting new technology enable researchers to design experiments in ways that were previously unaffordable or unimaginable.

The company’s technology produces picoliter-volume droplets at a rate of 10 million per hour. Each droplet is the functional equivalent of an individual test tube and can contain a single molecule, reaction, or cell. This versatile technology can adapt highly referenced assays for high-speed workflows with minimized process-induced bias or error.

RainDance’s initial application will focus on the targeted resequencing of the human genome — one of the fastest-growing segments of the $1 billion DNA sequencing market. This application will enable the high-resolution analysis of genetic variation between individuals and populations at a level unmatched by current methodology.

RainDance was founded in 2004 by scientists from Harvard University; the Medical Research Centre in Cambridge, England; and the ESPCI in Paris. The promise of this technology has attracted an outstanding Scientific Advisory Board. RainDance advisers include three Nobel Prize winners: Jean-Marie Lehn (Chemistry, 1987), Aaron Klug (Chemistry, 2002), and Sir Richard Roberts (Physiology or Medicine, 1993), as well as Sir Gregory Winter, joint head of the British Division of Protein and Nucleic Acids Chemistry at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge.

For more information, please visit http://www.raindancetechnologies.com/. For more information, please visit http://www.raindancetechnologies.com/.

# # #

Public Relations contact: Tiziani Whitmyre Inc., http://www.tizinc.com/

bookmark to del.icio.us

Technorati tags: , , , , , , , , ,

Tags: , , , , , , , ,
Posted in Biosciences |

« Older Entries
Newer Entries »

Industry PR is proudly powered by WordPress.
WordPress